Additionally, Rezvani et al. studied CD8+ T-cell responses to PRAME-derived epitopes in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) [158]. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.